Blog
Who Is Winning the Switzerland & Austria Autoinjectors Race? Inside the Moves of Ypsomed, SHL Medical, Sandoz & More
Company Analysis | Autoinjectors
Switzerland & Austria Autoinjectors Market: Company Analysis of Ypsomed, SHL Medical, Haselmeier, Novartis and Sandoz
We examined the products, recent developments, partnerships and financial disclosure of five key companies to see where each is placing its bets.
Download Free Sample Speak to an AnalystAbout This Analysis
The Switzerland and Austria autoinjectors market brings together two kinds of companies. Device platform makers design and manufacture autoinjectors, and pharmaceutical companies put their drugs inside those devices and sell them to patients. To see how the leading players are competing, we reviewed each company's profile, product pages, 17 recent-development announcements and financial publications.
1. Company Snapshot
This table compares all five companies by business model, lead product and current strategic focus.
| Company | Role | Key autoinjector products | Strategic focus |
|---|---|---|---|
| Ypsomed AG | Device platform maker | YpsoMate autoinjectors, YpsoLoop | Large-volume delivery |
| SHL Medical AG | Device platform maker | Autoinjector range, Molly, Reunite | Scale and capacity |
| Haselmeier (medmix) | Device platform maker | PiccoJect autoinjector | International distribution |
| Novartis AG | Pharma (branded) | Kesimpta pen | Subcutaneous delivery innovation |
| Sandoz Group AG | Pharma (biosimilars and generics) | Pyzchiva autoinjector | Biosimilars and GLP-1 |
2. Development Activity by Company
Counting each company's recent announcements shows who is making the most visible moves. Device makers account for 14 of the 17 development announcements (82%). SHL Medical and Ypsomed together account for 12, which reflects their role as the main platform suppliers behind many pharma launches.
Recent Development Announcements per Company
SHL Medical7Ypsomed5Haselmeier2Sandoz2Novartis1Device platform makerPharma companyBased on the 17 development links reviewed for this analysis.
3. Strategic Theme Analysis
We grouped each announcement by its main strategic theme. Partnerships are the most common move, followed by capacity investments and product launches. The pattern suggests that companies in this market grow mainly by locking in partners and adding manufacturing scale, not only by launching new devices.
Development Announcements by Main Theme (n = 17)
| 17 developments |
5 Partnerships (29%) 4 Capacity & tooling (24%) 4 Product & commercial launches (24%) 4 Other (sustainability, milestone, outreach, pipeline) (24%) |
4. Company vs Theme Heatmap
An announcement can cover more than one theme. For example, the Ypsomed and BD partnership is also about large-volume delivery. Mapping every theme against every company makes each company's focus clear.
Number of Announcements Touching Each Theme
| Partnerships | Capacity & tooling | Launches | Large-volume | Sustainability | Biosimilars & GLP-1 | |
|---|---|---|---|---|---|---|
| Ypsomed | 2 | 1 | 2 | 3 | 1 | – |
| SHL Medical | 2 | 3 | 1 | 1 | – | 1 |
| Haselmeier | 1 | – | 1 | – | 1 | – |
| Novartis | 1 | – | – | – | – | – |
| Sandoz | – | – | 1 | – | – | 2 |
Darker cells mean more announcements. One announcement can count toward several themes.
5. Partnership Network
Partnerships link the Swiss device makers to glass container suppliers, distributors and drug companies. The link between SHL Medical and Sandoz stands out: SHL's Molly platform powers Sandoz's Pyzchiva, Europe's first ustekinumab biosimilar autoinjector. It is the only direct device-to-pharma link among the five companies analysed.
Named Partnerships
Ypsomed SHL Medical Haselmeier Stevanato Group BD SCHOTT Pharma NIPRO (Japan) Sandoz High-dose and large-volume delivery Molly → Pyzchiva biosimilar autoinjector Exclusive PiccoJect distribution in Japan Novartis: collaboration on subcutaneous drug delivery (partner not named in source)Want full profiles of every company in this market?
The report includes detailed company profiles, product benchmarking, market share analysis and forecasts for Switzerland and Austria.
Get the Free Sample Report6. Product Portfolio Analysis
Device makers offer platforms that many drugs can use, while pharma companies sell a single drug-device combination. That difference shapes how each group competes.
Platform suppliers (B2B)
Ypsomed: autoinjector platforms, including a new model for volumes up to 5.5 mL and YpsoLoop, which Ypsomed calls the first autoinjector platform designed for circularity.
SHL Medical: a broad autoinjector range, the Reunite platform and the Molly platform. SHL also publishes educational content on autoinjector basics.
Haselmeier: PiccoJect, a disposable two-step autoinjector with 1 mL and 2.25 mL variants and a simplified eight-part design.
Drug-device products (B2C / patient)
Novartis: the Kesimpta pen, a self-injection pen for multiple sclerosis.
Sandoz: the Pyzchiva autoinjector, an ustekinumab biosimilar. Sandoz provides product information and self-injection guidance for patients.
7. Company Deep Dives
Ypsomed AG
Ypsomed's recent moves centre on high-dose delivery. It introduced an autoinjector for volumes up to 5.5 mL, integrated its platform with Stevanato Group for high-dose drugs, and expanded its partnership with BD for large-volume biologics. It also launched YpsoLoop for circularity and opened a new tool manufacturing facility in Solothurn.
What it signals: Ypsomed is positioning itself for the next generation of biologics that need larger doses, while also getting ahead on sustainability.
SHL Medical AG
SHL has shipped more than 1.5 billion autoinjectors. It is expanding capacity with a USD 220 million autoinjector site (also reported here) and SHL Advantec, a new sub-group for tooling and automation that brings together its tooling operations and several acquisitions. On the commercial side, its Molly platform powers Europe’s first ustekinumab biosimilar autoinjector. It is also working with SCHOTT Pharma on large-volume home injections and showcasing its solutions at industry events.
What it signals: SHL is competing on scale and supply security, controlling more of its own tooling and automation so it can deliver high volumes reliably.
Haselmeier (medmix)
Haselmeier launched PiccoJect at Pharmapack in Paris, calling it its first fully featured autoinjector. It later signed an exclusive partnership with NIPRO to distribute PiccoJect in Japan.
What it signals: Haselmeier is a smaller challenger that is using distribution partners to reach new regions quickly.
Novartis AG
Novartis sells the Kesimpta pen for at-home self-injection and has announced a collaboration to innovate subcutaneous drug delivery.
What it signals: Novartis sees subcutaneous self-injection as a way to make its biologics more convenient for patients.
Sandoz Group AG
Sandoz launched the Pyzchiva autoinjector, the first commercially available ustekinumab biosimilar autoinjector in Europe. The US FDA has also accepted its applications for an in-house generic tirzepatide.
What it signals: For Sandoz, the autoinjector is a key selling point for biosimilars, and GLP-1 pens look like its next major opportunity.
8. Financial Transparency Analysis
The five companies differ sharply in how much financial detail is publicly available. Novartis, Sandoz and Ypsomed publish full annual and financial reports. For SHL Medical and Haselmeier, only third-party revenue estimates are available. That makes it harder to benchmark two of the most important device suppliers in the market.
| Company | Financial source | Disclosure level |
|---|---|---|
| Novartis AG | Annual Report 2025 |
|
| Sandoz Group AG | 2025 report · 2024 report |
|
| Ypsomed AG | Financial publications |
|
| SHL Medical AG | Latka profile |
|
| Haselmeier (medmix) | Growjo profile |
|
9. Key Takeaways
| 01 | Device makers drive the market 14 of 17 announcements come from Ypsomed, SHL Medical and Haselmeier. |
| 02 | Partnerships are the top strategy 5 of 17 announcements are partnerships, the largest single theme. |
| 03 | Large-volume delivery is the next frontier Ypsomed, together with SHL and SCHOTT, is targeting doses above standard 1 mL pens. |
| 04 | Biosimilars connect device and pharma SHL Molly and Sandoz Pyzchiva show how device platforms help biosimilars compete. |
Benchmarking competitors or looking for a partner?
Get the full competitive landscape at a special price.
Check Discount AvailabilityFrequently Asked Questions
Which companies lead the Switzerland and Austria autoinjectors market?
Key companies include the device platform makers Ypsomed, SHL Medical and Haselmeier (medmix), and the pharmaceutical companies Novartis and Sandoz.
Which company is the most active?
SHL Medical has the most recent development announcements (7), followed by Ypsomed (5).
What strategies are companies using?
Partnerships, manufacturing capacity expansion, large-volume devices, sustainable platforms and biosimilar launches.
Sources
Ypsomed AG
About · Contact · Product · Recent development 1 · Website · Financials · Recent development 2 · Recent development 3 · Recent development 4 · Recent development 5
SHL Medical AG
About · Contact · Product 1 · Recent development 1 · Website · Financials · Product 2 · Recent development 2 · Product 3 · Recent development 3 · Recent development 4 · Recent development 5 · Recent development 6 · Recent development 7
Haselmeier (medmix)
About · Contact · Product · Recent development 1 · Website · Financials · Recent development 2
Novartis AG
About · Contact · Product · Recent development · Website · Financials
Sandoz Group AG
About · Contact · Product 1 · Recent development 1 · Website · Financials 1 · Product 2 · Recent development 2 · Financials 2
Get the Full Switzerland & Austria Autoinjectors Market Report
Company profiles, competitive benchmarking, market size and forecasts in one report.
Download Sample Make an Inquiry Request Discount